Equities

Shanghai Aladdin Biochemical Technology Co Ltd

688179:SHH

Shanghai Aladdin Biochemical Technology Co Ltd

Actions
Basic MaterialsChemicals
  • Price (CNY)9.17
  • Today's Change-0.21 / -2.24%
  • Shares traded1.27m
  • 1 Year change-36.73%
  • Beta--
Data delayed at least 15 minutes, as of Jul 08 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shanghai Aladdin Biochemical Technology Co Ltd is a China-based company mainly engaged in the research and development, production and sales of scientific research reagents. The Company's businesses cover the four major areas of high-end chemistry, life sciences, analytical chromatography and materials science, and a small amount of experimental consumables. The Company's products are used in universities, scientific research institutes, biomedicine, new materials, new energy, energy conservation and environmental protection, aerospace and other fields. The Company independently builds Aladdin brand scientific research reagents and Silicon Valley brand experimental consumables, mainly relying on its own e-commerce platform www.aladdin-e.com to achieve online sales. The Company mainly conducts its businesses in the China market.

  • Revenue in CNY (TTM)414.81m
  • Net income in CNY85.68m
  • Incorporated2009
  • Employees566.00
  • Location
    Shanghai Aladdin Biochemical Technology Co Ltd16F, South Tower, No. 36Xinjinqiao Road, Pudong New AreaSHANGHAI 201206ChinaCHN
  • Phone+86 2 150560989
  • Fax+86 2 150323701
  • Websitehttps://www.aladdin-e.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
688179:SHH since
announced
Transaction
value
Shanghai Yuanye Bio-Technology Co LtdAnnounced19 Mar 202419 Mar 2024Announced-38.74%25.13m
Data delayed at least 15 minutes, as of Jul 08 2024.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Xinjiang Bai Hua Cun Pharma Tech Co Ltd384.44m26.95m2.10bn787.0077.852.89--5.470.07080.07081.011.910.3671.381.79488,492.202.57-4.593.60-6.2448.3824.097.01-18.401.44--0.0021--5.54-2.50137.33---21.00--
Hinova Pharmaceuticals Inc0.00-266.00m2.51bn179.00--1.89-----2.69-2.690.0013.390.00105.68--0.00-17.03-31.86-18.39-37.18-------25,578.2411.83--0.0097---100.00--2.44--124.37--
Shanghai Aladdin Biochemical Tech Co Ltd414.81m85.68m2.60bn566.0026.042.47--6.270.36020.36021.383.800.28030.38989.21732,874.105.798.836.209.6160.0861.4920.6626.858.00--0.251945.716.5519.36-7.489.9531.41--
Bide Pharmatech Co Ltd1.10bn98.72m2.75bn846.0027.841.35--2.501.091.0912.1422.500.45851.094.761,302,686.004.06--4.62--38.38--8.86--5.29--0.0416--30.94---24.94------
Jiangsu Yahong Meditech Co Ltd38.05m-420.35m3.00bn394.00--1.30--78.80-0.7375-0.73750.06684.030.01423.053.7696,573.63-15.68-15.80-16.54-16.4877.7255.32-1,106.10-9,445.9111.34--0.0684--52,594.79---62.42--64.28--
Qingdao Vland Biotech INC1.25bn82.87m3.21bn1.57k38.191.87--2.560.33260.33265.026.810.44313.424.33797,663.403.805.785.777.8945.3846.138.5810.340.8387149.270.289633.593.078.0515.56-0.650724.68-6.89
Shanghai Medicilon Inc1.17bn-172.33m3.66bn2.60k--1.48--3.12-1.24-1.249.1118.340.42056.631.64451,437.20-6.179.34-7.9711.7312.4836.71-14.6814.932.63--0.122920.18-17.6833.26-109.82--23.60--
Data as of Jul 08 2024. Currency figures normalised to Shanghai Aladdin Biochemical Technology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

3.60%Per cent of shares held by top holders
HolderShares% Held
Huashang Fund Management Co., Ltd.as of 31 Dec 20235.42m1.95%
GF Fund Management Co., Ltd.as of 31 Dec 20231.94m0.70%
Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023907.75k0.33%
Lion Fund Management Co., Ltd.as of 31 Dec 2023468.70k0.17%
JX Asset Management Co.,Ltdas of 31 Dec 2023363.09k0.13%
Nanhua Fund Management Co. Ltd.as of 31 Dec 2023301.56k0.11%
China Universal Asset Management Co., Ltd.as of 31 Dec 2023251.48k0.09%
First-Trust Fund Management Co., Ltd.as of 31 Dec 2023190.38k0.07%
Golden Trust Sinopac Fund Management Co., Ltd.as of 31 Dec 202398.00k0.04%
Orient Fund Management Co., Ltd.as of 31 Dec 202349.00k0.02%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.